跳至主要内容

Five Inflammatory Diseases Erupt from Common Genetic Ground

  It isn’t exactly earth-shaking news that a number of inflammatory diseases, including Crohn’s disease and ulcerative colitis, commonly occur together in individuals and families. Also, it has long been suspected that these inflammatory processes emanate from a shared fault, either environmental or genetic. But now, thanks to a global survey, the subterranean connection has finally been revealed. It is mainly genetic.



At present, as the pathogenesis of inflammatory and immunological diseases is unclear, there are few effective therapeutic drugs available in clinical practice. In such a context, the appropriate preclinical research techniques and models are required to help companies and researchers further develop and evaluate new drugs. Our Preclinical Pharmacodynamics Department has been deeply involved in this field for years, developing reliable animal-based efficacy evaluation models aimed at different targets and pathways, thus facilitating the clinical transformation of new drugs.

   

        The genetic substratum for the five diseases—ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and primary sclerosing cholangitis—was unearthed in a study that was led by scientists from Queensland University of Technology (QUT), Brisbane, Australia, and Christian-Albrechts-University, Kiel,  Germany. These scientists, who pieced together information provided by 50 different research centers from around the world, ultimately determined that the five diseases have common genetic ground, and that the ground consists of hundreds of genes.

   

        The details appeared March 14 in the journal Nature Genetics, in an article entitled, “Analysis of Five Chronic Inflammatory Diseases Identifies 27 New Associations and Highlights Disease-Specific Patterns at Shared Loci.” The article describes how the researchers combined Immunochip genotype data for 52,262 cases and 34,213 controls of European ancestry, drawing from what are “currently the largest available genetic data sets in five clinically related seronegative immune-driven phenotypes,” to explore the extent of sharing of genetic susceptibility loci.


   

        “Using high-density genotype data from more than 86,000 individuals of European ancestry, we identified 244 independent multidisease signals, including 27 new genome-wide significant susceptibility loci and 3 unreported shared risk loci,” wrote the study’s authors. “Complex pleiotropy was supported when contrasting multidisease signals with expression data sets from human, rat, and mouse together with epigenetic and expressed enhancer profiles. The comorbidities among the five immune diseases were best explained by biological pleiotropy rather than heterogeneity.”

   

        According to Matthew Brown, M.D., a co-senior author of the study and a professor at QUT’s Institute of Health and Biomedical Innovation, the new gene discoveries pointed to some potential new therapies, including agents already in use for other diseases which can now be trialed in these conditions very promptly.

   

        “The discoveries have shed new light onto the causes of these diseases, such as identifying genetic risk variants which most likely work by affecting the bacteria present in the gut, in turn causing inflammation in joints, the liver or the gut itself,” noted Professor Brown. “These study findings are a major leap forward in our understanding of these common but difficult-to-treat diseases.”

   

        The diseases affect about 3% of the world’s population and are often debilitating and difficult to treat. That these diseases could be traced to shared genetic risk factors, rather than found to give rise to each other, lends credence to the study’s overall approach—looking across the genetics of multiple diseases to resolve overlapping associations into discrete pathways, and to explore details of apparently shared etiologies.

   

    “It has been known for over 50 years these conditions frequently occur together in individuals and families. We now know this is mainly because the genes involved affect the risk of many diseases, and that the diseases are therefore very similar in their underlying causes, even if they present in such different ways,” concluded Professor Brown. “This research has pointed us to several different potential therapeutic targets for these diseases, for which there is a huge global need for better therapies.”

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati